STOCK TITAN

Nature's Sunshine Reports Strong First Quarter 2025 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Nature's Sunshine (NATR) reported strong Q1 2025 results with net sales up 2% to $113.2 million (5% in constant currency) and GAAP net income up 104% to $4.7 million. Adjusted EBITDA increased 20% to $11.0 million. The company saw exceptional growth in Asia and Europe, with markets like Taiwan, Japan, and Central Europe delivering strong double-digit growth. Gross profit margin improved to 72.1% from 71.2%. The board authorized a new $25 million share repurchase program, adding to the $8.3 million remaining from the previous authorization. The company maintains its full-year 2025 guidance with net sales expected between $445-$470 million and adjusted EBITDA between $38-$44 million.

Nature's Sunshine (NATR) ha riportato risultati solidi nel primo trimestre del 2025 con le vendite nette in aumento del 2% a 113,2 milioni di dollari (5% a valuta costante) e l'utile netto GAAP in crescita del 104% a 4,7 milioni di dollari. L'EBITDA rettificato è aumentato del 20% raggiungendo 11,0 milioni di dollari. L'azienda ha registrato una crescita eccezionale in Asia e Europa, con mercati come Taiwan, Giappone e Europa Centrale che hanno mostrato una forte crescita a doppia cifra. Il margine lordo è migliorato al 72,1% rispetto al 71,2%. Il consiglio di amministrazione ha autorizzato un nuovo programma di riacquisto azionario da 25 milioni di dollari, aggiungendosi agli 8,3 milioni di dollari residui dalla precedente autorizzazione. La società conferma le previsioni per l'intero anno 2025, con vendite nette attese tra 445 e 470 milioni di dollari e EBITDA rettificato tra 38 e 44 milioni di dollari.
Nature's Sunshine (NATR) reportó sólidos resultados en el primer trimestre de 2025 con ventas netas que aumentaron un 2% hasta 113,2 millones de dólares (5% en moneda constante) y ingreso neto GAAP que creció un 104% hasta 4,7 millones de dólares. El EBITDA ajustado aumentó un 20% hasta 11,0 millones de dólares. La compañía experimentó un crecimiento excepcional en Asia y Europa, con mercados como Taiwán, Japón y Europa Central mostrando un fuerte crecimiento de dos dígitos. El margen bruto mejoró al 72,1% desde el 71,2%. El consejo autorizó un nuevo programa de recompra de acciones por 25 millones de dólares, sumándose a los 8,3 millones restantes de la autorización previa. La empresa mantiene su guía para todo el año 2025, con ventas netas esperadas entre 445 y 470 millones de dólares y EBITDA ajustado entre 38 y 44 millones de dólares.
Nature's Sunshine (NATR)는 2025년 1분기에 순매출이 2% 증가한 1억 1,320만 달러(환율 고정 기준 5% 증가)와 GAAP 순이익이 104% 증가한 470만 달러를 기록하며 강력한 실적을 보고했습니다. 조정 EBITDA는 20% 증가한 1,100만 달러였습니다. 대만, 일본, 중부 유럽 등 아시아와 유럽 시장에서 두 자릿수의 강력한 성장을 보이며 예외적인 성장을 달성했습니다. 총이익률은 71.2%에서 72.1%로 개선되었습니다. 이사회는 이전 승인에서 남은 830만 달러에 더해 2,500만 달러 규모의 새로운 자사주 매입 프로그램을 승인했습니다. 회사는 2025년 전체 연간 가이던스를 유지하며, 순매출은 4억 4,500만~4억 7,000만 달러, 조정 EBITDA는 3,800만~4,400만 달러로 예상하고 있습니다.
Nature's Sunshine (NATR) a publié de solides résultats pour le premier trimestre 2025 avec des ventes nettes en hausse de 2 % à 113,2 millions de dollars (5 % en devise constante) et un bénéfice net GAAP en progression de 104 % à 4,7 millions de dollars. L'EBITDA ajusté a augmenté de 20 % pour atteindre 11,0 millions de dollars. La société a connu une croissance exceptionnelle en Asie et en Europe, avec des marchés comme Taïwan, le Japon et l'Europe centrale affichant une forte croissance à deux chiffres. La marge brute s'est améliorée à 72,1 % contre 71,2 %. Le conseil d'administration a autorisé un nouveau programme de rachat d'actions de 25 millions de dollars, s'ajoutant aux 8,3 millions restants de l'autorisation précédente. La société maintient ses prévisions pour l'année 2025, avec des ventes nettes attendues entre 445 et 470 millions de dollars et un EBITDA ajusté compris entre 38 et 44 millions de dollars.
Nature's Sunshine (NATR) meldete starke Ergebnisse für das erste Quartal 2025 mit einem Nettoumsatzanstieg von 2 % auf 113,2 Millionen US-Dollar (5 % bei konstanter Währung) und einem GAAP-Nettogewinnanstieg von 104 % auf 4,7 Millionen US-Dollar. Das bereinigte EBITDA stieg um 20 % auf 11,0 Millionen US-Dollar. Das Unternehmen verzeichnete außergewöhnliches Wachstum in Asien und Europa, wobei Märkte wie Taiwan, Japan und Mitteleuropa ein starkes zweistelliges Wachstum zeigten. Die Bruttogewinnmarge verbesserte sich von 71,2 % auf 72,1 %. Der Vorstand genehmigte ein neues Aktienrückkaufprogramm in Höhe von 25 Millionen US-Dollar, zusätzlich zu den verbleibenden 8,3 Millionen US-Dollar aus der vorherigen Genehmigung. Das Unternehmen hält seine Prognose für das Gesamtjahr 2025 aufrecht, mit erwarteten Nettoumsätzen zwischen 445 und 470 Millionen US-Dollar sowie einem bereinigten EBITDA zwischen 38 und 44 Millionen US-Dollar.
Positive
  • Net income increased 104% to $4.7 million ($0.25 per share) vs $2.3 million ($0.12 per share) YoY
  • Adjusted EBITDA grew 20% to $11.0 million
  • Gross profit margin improved to 72.1% from 71.2%
  • Strong growth in Asia (5.3%) and Europe (8.2%)
  • New $25 million share repurchase program authorized
  • Company maintains strong balance sheet with $86.5 million cash and zero debt
Negative
  • North America sales declined 4.1%
  • Latin America sales decreased 8.2%
  • Volume incentives increased to 30.8% of net sales from 30.2%
  • NSP China net income decreased to $0.7 million from $0.8 million

Insights

Nature's Sunshine delivered strong Q1 results with 104% net income growth and 20% EBITDA growth despite regional performance variations.

Nature's Sunshine reported strong financial results for Q1 2025, with both revenue growth and significant profit improvement. Revenue increased 2% to $113.2 million, though when accounting for currency fluctuations, constant currency growth was more robust at 5%. Most impressively, GAAP net income more than doubled, growing 104% to $4.7 million ($0.25 per share), while adjusted EBITDA rose 20% to $11.0 million.

Performance varied significantly by region. Asia sales grew 5.3% (10.1% in constant currency) to $48.7 million, while Europe increased 8.2% to $24.1 million. However, North America declined 4.1% to $35.0 million, and Latin America fell 8.2% to $5.5 million. Management specifically highlighted Taiwan, Japan, and Central Europe as markets delivering "strong double-digit growth."

Gross margin improved to 72.1% from 71.2%, which the company attributed to price increases and effective savings initiatives. Volume incentives increased slightly to 30.8% of net sales (from 30.2%), primarily due to promotional timing and market mix changes. SG&A expenses decreased slightly to $40.6 million (35.8% of sales) from $40.8 million (36.7% of sales), reflecting the company's efforts to streamline global expenses.

The board's authorization of a new $25 million share repurchase program, supplementing $8.3 million remaining from the previous authorization, signals confidence in the company's financial position. With $86.5 million in cash and zero debt, Nature's Sunshine maintains significant financial flexibility.

Operating cash flow was $2.6 million for the quarter, up from $2.2 million in Q1 2024, while capital expenditures decreased to $1.1 million from $3.7 million. Management maintained its full-year 2025 guidance of $445-$470 million in net sales and $38-$44 million in adjusted EBITDA, suggesting continued confidence despite "tremendous amount of uncertainty in the market" noted by the CEO.

LEHI, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (Nasdaq: NATR) ("Nature’s Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2025.

First Quarter 2025 Financial Summary vs. Same Year-Ago Quarter

  • Net sales were up 2% to $113.2 million compared to $111.0 million (up 5% in constant currency).
  • GAAP net income attributable to common shareholders was up 104% to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share.
  • Adjusted EBITDA was up 20% to $11.0 million compared to $9.2 million.

Capital Allocation

Nature’s Sunshine announced today that its board of directors authorized the repurchase of up to $25 million of the Company’s common shares. As of March 31, 2025, the Company had $8.3M remaining on its previous authorization. Repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations.

Management Commentary

“2025 got off to a strong start, as first quarter revenue came in at $113 million, up 5% on a constant currency basis, and adjusted EBITDA came in at $11 million, up 20% versus prior year,” said Terrence Moorehead, CEO of Nature’s Sunshine.

“We’re particularly pleased with the exceptional growth we’re seeing in Asia and Europe where markets like Taiwan, Japan and Central Europe continue to deliver strong double-digit growth. We’re also pleased to see early signs of stabilization in North America and continued improvements to gross margin. Despite the tremendous amount of uncertainty in the market, we remain confident in the underlying health of our business, and our performance reflects the power of our global growth strategies. In addition, our Board has authorized the repurchase of up to $25 million in common stock, supplementing the $8.3 million remaining under the current authorization, as we continue to make disciplined investments with the highest potential return for our shareholders.”

First Quarter 2025 Financial Results

  Net Sales by Operating Segment (Amounts in Thousands)
Three Months Ended March 31, 2025 2024 Percent
Change
 Impact of
Currency
Exchange
 Percent
Change
Excluding
Impact of
Currency
Asia $48,653  $46,220  5.3% $(2,214) 10.1%
Europe  24,114   22,296  8.2   (90) 8.6 
North America  35,018   36,525  (4.1)  (166) (3.7)
Latin America and Other  5,463   5,952  (8.2)  (271) (3.7)
  $113,248  $110,993  2.0% $(2,741) 4.5%
                   

Net sales in the first quarter increased 2% to $113.2 million compared to $111.0 million in the same year-ago quarter. Excluding the impact from foreign exchange rates, net sales in the first quarter of 2025 increased 5% compared to the year-ago quarter.

Gross profit margin in the first quarter increased to 72.1% compared to 71.2% in the year-ago quarter. The increase was driven by price increases and effective savings initiatives.

Volume incentives as a percentage of net sales were 30.8% compared to 30.2% in the year-ago quarter. The increase was primarily due to the timing of promotional incentives and changes in market mix.

Selling, general and administrative expenses ("SG&A") in the first quarter were $40.6 million compared to $40.8 million in the year‐ago quarter. The decrease was primarily related to the streamlining of our global expenses and reduced service fees due to China's lower net sales. As a percentage of net sales, SG&A expenses were 35.8% for the first quarter of 2025 compared to 36.7% in the year-ago quarter.

Operating income in the first quarter increased to $6.2 million, or 5.4% of net sales, compared to $4.6 million, or 4.2% of net sales, in the year-ago quarter.

Other income, net, in the first quarter of 2025 was $0.9 million compared to $31,000 in the first quarter of 2024. Other income, net, primarily consisted of foreign exchange gains that resulted from net changes in foreign currencies. The provision for income taxes was $2.2 million in the first quarter of 2025 compared to $2.2 million for the year-ago quarter.

GAAP net income attributable to common shareholders increased to $4.7 million, or $0.25 per diluted common share, compared to $2.3 million, or $0.12 per diluted common share, in the first quarter of 2024. Net income attributable to NSP China decreased to $0.7 million, or $0.04 per diluted common share, for the first quarter of 2025, compared to $0.8 million, or $0.04 per diluted common share, for the first quarter of 2024.

Adjusted EBITDA in the first quarter increased 20% to $11.0 million compared to $9.2 million in the year-ago quarter. The increase was driven primarily by the aforementioned increase in net sales. Adjusted EBITDA, which is a non-GAAP financial measure, is defined here as net income from continuing operations before taxes, depreciation, amortization, and other income (loss) adjusted to exclude share-based compensation expense and certain noted adjustments. A reconciliation of net income to adjusted EBITDA is provided in the attached financial tables.

Balance Sheet and Cash Flow

Net cash provided by operating activities was $2.6 million for the three months ended March 31, 2025, compared to $2.2 million in the prior year period. Capital expenditures during the three months ended March 31, 2025, totaled $1.1 million compared to $3.7 million in the comparable period of 2024. During the three months ended March 31, 2025, the Company repurchased 38,000 shares at a total cost of $0.5 million or $12.47 per share. As of March 31, 2025, the Company had cash and cash equivalents of $86.5 million and zero debt.

Outlook

Nature's Sunshine continues to expect full year 2025 net sales to range between $445 - $470 million and adjusted EBITDA to range between $38 - $44 million.

Conference Call

The Company will hold a conference call today at 5:00 p.m. Eastern time to discuss its first quarter of 2025 results.

Date: Tuesday, May 6, 2025
Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)
Toll-free dial-in number: 1-800-717-1738
International dial-in number: 1-646-307-1865
Conference ID: 16234

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

The conference call will be broadcast live and available for replay here and via the Events section of the Nature’s Sunshine website here.

A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through May 20, 2025.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 1116234

About Nature’s Sunshine Products

Nature’s Sunshine Products (Nasdaq: NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature’s Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety, and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements regarding the Company’s future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including expected improvements in gross profit and gross margin. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following:

  • failure to comply with laws and regulations relating to trade restrictions and export controls;
  • laws and regulations regarding direct selling that may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
  • current and potential future extensive government regulations to which the Company’s products, business practices and manufacturing activities are subject;
  • registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
  • legal challenges to the Company’s direct selling program or to the classification of its independent consultants;
  • failure of the Company’s independent consultants to comply with advertising laws;
  • product liability claims;
  • impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
  • the Company’s ability to attract and retain independent consultants;
  • the loss of one or more key independent consultants who have a significant sales network;
  • potential for increased liability and compliance costs relating to the Company’s joint venture for operations in China with Fosun Industrial Co., Ltd.;
  • the effect of fluctuating foreign exchange rates;
  • liabilities and obligations arising from improper activity by the Company’s independent consultants;
  • changes to the Company’s independent consultant compensation plans;
  • geopolitical issues, conflicts or other global events;
  • negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company’s customers to purchase products;
  • risks associated with the manufacturing of the Company’s products;
  • supply chain disruptions, manufacturing interruptions or delays or the failure to accurately forecast customer demand;
  • failure to timely and effectively obtain shipments of products from our suppliers and deliver products to our independent consultants and customers;
  • the impact of shifting tariff regimes and trade policies between U.S. and the other countries where we operate;
  • uncertainties relating to the application of transfer pricing, duties, value-added taxes and other tax regulations, and changes thereto;
  • failure to maintain an effective system of internal controls over financial reporting;
  • cybersecurity threats and exposure to data loss;
  • the storage, processing and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
  • reliance on information technology infrastructure; and
  • the sufficiency of trademarks and other intellectual property rights.

These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption “Risk Factors” in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.

All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.

Non-GAAP Financial Measures

We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations.

We utilize the non-GAAP measure of adjusted EBITDA in the evaluation of our operations and believe that this measure is a useful indicators of our ability to fund our business. This non-GAAP financial measure should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income as an indicator of our operating performance.

Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature’s Sunshine Products’ performance in relation to other companies. We have included a reconciliation of net income, the most comparable GAAP measure, to adjusted EBITDA, in the attached financial table.

Net sales in local currency removes, from net sales in U.S. dollars, the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. This is accomplished by translating the current period's net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period.

We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

With respect to our adjusted EBITDA outlook for the full year 2025, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to warrant liabilities and stock based compensation. For the same reasons, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

Investor Relations:

Gateway Group, Inc.
Cody Slach
1-949-574-3860
NATR@gateway-grp.com

 
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands, except per share information)
(Unaudited)
     
Three Months Ended March 31, 2025 2024
Net sales $113,248  $110,993 
Cost of sales  31,651   32,015 
Gross profit  81,597   78,978 
     
Operating expenses:    
Volume incentives  34,844   33,570 
Selling, general and administrative  40,581   40,784 
Operating income  6,172   4,624 
Other income:    
Interest and other income, net  205   63 
Interest expense  (21)  (12)
Foreign exchange gains (losses), net  753   (20)
   937   31 
Income before provision for income taxes  7,109   4,655 
Provision for income taxes  2,225   2,165 
Net income  4,884   2,490 
Net income attributable to noncontrolling interests  137   169 
Net income attributable to common shareholders $4,747  $2,321 
     
Basic and diluted net income per common share:    
     
Basic earnings per share attributable to common shareholders $0.26  $0.12 
     
Diluted earnings per share attributable to common shareholders $0.25  $0.12 
     
Weighted average basic common shares outstanding  18,486   18,828 
Weighted average diluted common shares outstanding  18,846   19,224 
         


 
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)
     
  March 31,
2025
 December 31,
2024
Assets    
Current assets:    
Cash and cash equivalents $86,486  $84,700 
Accounts receivable, net of allowance for doubtful accounts of $91 and $97, respectively  11,413   9,477 
Inventories  64,928   59,443 
Prepaid expenses and other  7,955   6,959 
Total current assets  170,782   160,579 
     
Property, plant and equipment, net  37,701   39,585 
Operating lease right-of-use assets  13,461   12,799 
Restricted investment securities - trading  937   915 
Deferred income tax assets  20,019   17,644 
Other assets  9,802   9,333 
Total assets $252,702  $240,855 
     
Liabilities and Shareholders’ Equity    
Current liabilities:    
Accounts payable $9,865  $8,912 
Accrued volume incentives and service fees  22,697   20,563 
Accrued liabilities  24,859   25,399 
Deferred revenue  2,487   2,774 
Income taxes payable  6,542   4,117 
Current portion of operating lease liabilities  4,291   3,927 
Total current liabilities  70,741   65,692 
     
Liability related to unrecognized tax benefits  627   628 
Long-term portion of operating lease liabilities  10,557   10,277 
Deferred compensation payable  937   915 
Deferred income tax liabilities  1,160   1,007 
Other liabilities  1,580   1,345 
Total liabilities  85,602   79,864 
     
Shareholders’ equity:    
Common stock, no par value, 50,000 shares authorized, 18,474 and 18,483 shares issued and outstanding, respectively  115,146   114,577 
Retained earnings  62,154   57,407 
Noncontrolling interest  5,815   5,678 
Accumulated other comprehensive loss  (16,015)  (16,671)
Total shareholders’ equity  167,100   160,991 
Total liabilities and shareholders’ equity $252,702  $240,855 
         


 
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
(Unaudited)
     
Three Months Ended March 31, 2025 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $4,884  $2,490 
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization  3,499   3,160 
Non-cash lease expense  1,479   1,197 
Share-based compensation expense  1,300   1,369 
Deferred income taxes  (1,982)  (157)
Purchase of trading investment securities  (61)  (14)
Proceeds from sale of trading investment securities  1   21 
Realized and unrealized losses (gains) on investments  37   (62)
Foreign exchange losses (gains)  (753)  20 
Changes in assets and liabilities:    
Accounts receivable  (1,786)  (1,136)
Inventories  (5,053)  3,389 
Prepaid expenses and other current assets  (1,242)  (2,415)
Other assets  (157)  (409)
Accounts payable  644   1,099 
Accrued volume incentives and service fees  1,986   (101)
Accrued liabilities  (1,116)  (6,802)
Deferred revenue  (293)  108 
Lease liabilities  (1,502)  (1,002)
Income taxes payable  2,283   965 
Liability related to unrecognized tax benefits  418   415 
Deferred compensation payable  23   55 
Net cash provided by operating activities  2,609   2,190 
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property, plant and equipment  (1,110)  (3,689)
Net cash used in investing activities  (1,110)  (3,689)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from revolving credit facility  735   4,808 
Principal payments of revolving credit facility  (735)  (2,701)
Payments related to tax withholding for net-share settled equity awards  (255)  (152)
Repurchase of common stock  (476)  (1,848)
Net cash provided by (used in) financing activities  (731)  107 
Effect of exchange rates on cash and cash equivalents  1,018   (3,208)
Net increase (decrease) in cash and cash equivalents  1,786   (4,600)
Cash and cash equivalents at the beginning of the period  84,700   82,373 
Cash and cash equivalents at the end of the period $86,486  $77,773 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for income taxes, net of refunds $1,875  $1,383 
Cash paid for interest  15   12 
         


 
NATURE’S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
(Amounts in thousands)
(Unaudited)
     
Three Months Ended March 31, 2025 2024
Net income $4,884  $2,490 
Adjustments:    
Depreciation and amortization  3,499   3,160 
Share-based compensation expense  1,300   1,369 
Other income, net*  (937)  (31)
Provision for income taxes  2,225   2,165 
Adjusted EBITDA $10,971  $9,153 
         

* Other income, net is primarily comprised of foreign exchange gains, interest income, and interest expense.


FAQ

What were Nature's Sunshine (NATR) key financial results for Q1 2025?

In Q1 2025, NATR reported net sales of $113.2M (up 2%), net income of $4.7M (up 104%), and adjusted EBITDA of $11.0M (up 20%). Earnings per share were $0.25 compared to $0.12 in Q1 2024.

How much is Nature's Sunshine's new share repurchase program?

Nature's Sunshine's board authorized a new $25 million share repurchase program, in addition to the $8.3 million remaining from the previous authorization.

What is Nature's Sunshine's (NATR) guidance for 2025?

NATR expects full-year 2025 net sales between $445-$470 million and adjusted EBITDA between $38-$44 million.

How did Nature's Sunshine perform in different regions during Q1 2025?

Asia sales grew 5.3%, Europe increased 8.2%, while North America declined 4.1% and Latin America decreased 8.2%.

What is Nature's Sunshine's current cash position and debt status?

As of March 31, 2025, Nature's Sunshine had $86.5 million in cash and cash equivalents with zero debt.
Nature’S Sun

NASDAQ:NATR

NATR Rankings

NATR Latest News

NATR Stock Data

221.25M
14.42M
20.58%
67.58%
0.32%
Packaged Foods
Pharmaceutical Preparations
Link
United States
LEHI